* AnaptysBio Inc ANAB.OQ ANAB.O is expected to show a
rise in
quarterly revenue when it reports results on May 9 (estimated)
for the period ending March 31 2024
* The San Diego California-based company is expected to
report a
188.7% increase in revenue to $3.967 million from $1.37 million
a year ago, according to the mean estimate from 10 analysts,
based on LSEG data.
* LSEG's mean analyst estimate for AnaptysBio Inc is for a
loss
of $1.57 per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 7 "strong buy" or "buy," 3
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts had fallen by
about 1.1%
in the last three months.
* Wall Street's median 12-month price target for AnaptysBio
Inc is
$47.00, above its last closing price of $25.77.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT ESTIMATE MET, SE %
E® MISSED
Dec. 31 2023 -1.62 -1.60 -1.59 Beat 0.7
Sep. 30 2023 -1.80 -1.79 -1.41 Beat 21.4
Jun. 30 2023 -1.83 -1.70 -1.50 Beat 11.6
Mar. 31 2023 -1.08 -1.05 -1.58 Missed -50.8
Dec. -0.96 -0.96 -0.93 Beat 2.8
31 2022
Sep. 30 2022 -0.65 -0.72 -1.18 Missed -63.1
Jun. 30 2022 -0.89 -1.02 -1.15 Missed -12.6
Mar. 31 2022 -1.02 -0.99 -1.31 Missed -31.7
This summary was machine generated May 7 at 12:06 GMT. All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)